LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of high-value human therapeutics, today announced that the amended registration and definitive proxy statement filed with the Securities and Exchange Commission (SEC) on Thursday, August 7, 2008, has been declared effective by the SEC.
